Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Bond

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Journal of Blood Medicine|May 27, 2017
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumabDavid A Bond, Lapo Alinari
Current Hematologic Malignancy Reports|April 28, 2019
Targeting BTK in CLL: Beyond IbrutinibDavid A Bond, Jennifer A Woyach
Hematology/Oncology Clinics of North America|August 31, 2020
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell LymphomaDavid A Bond, Kami J Maddocks
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?David A Bond, Ajay K Gopal
Oncotargets and Therapy|August 6, 2020
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to DateYazeed Sawalha, David A Bond, Lapo Alinari
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directionsDavid A Bond, Lapo Alinari, Kami Maddocks
Journal of Clinical Medicine|April 3, 2021
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future DirectionsDavid A Bond, Peter Martin, Kami J Maddocks
Chest|September 4, 2020
Bias and Racism Teaching Rounds at an Academic Medical CenterQuinn Capers, David A Bond, Uday S Nori
Clinical Lymphoma, Myeloma & Leukemia|December 31, 2018
Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin LymphomaDavid A Bond, Emily Dotson, Farrukh T Awan, et al.
Leukemia & Lymphoma|November 15, 2016
Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting doseDavid A Bond, Ying Huang, Amy S Ruppert, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Journal of Blood Medicine|May 27, 2017
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumabDavid A Bond, Lapo Alinari
Current Hematologic Malignancy Reports|April 28, 2019
Targeting BTK in CLL: Beyond IbrutinibDavid A Bond, Jennifer A Woyach
Hematology/Oncology Clinics of North America|August 31, 2020
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell LymphomaDavid A Bond, Kami J Maddocks
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?David A Bond, Ajay K Gopal
Oncotargets and Therapy|August 6, 2020
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to DateYazeed Sawalha, David A Bond, Lapo Alinari
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directionsDavid A Bond, Lapo Alinari, Kami Maddocks
Journal of Clinical Medicine|April 3, 2021
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future DirectionsDavid A Bond, Peter Martin, Kami J Maddocks
Chest|September 4, 2020
Bias and Racism Teaching Rounds at an Academic Medical CenterQuinn Capers, David A Bond, Uday S Nori
Clinical Lymphoma, Myeloma & Leukemia|December 31, 2018
Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin LymphomaDavid A Bond, Emily Dotson, Farrukh T Awan, et al.
Leukemia & Lymphoma|November 15, 2016
Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting doseDavid A Bond, Ying Huang, Amy S Ruppert, et al.
Pageof 6